文献速递腹部技术与安全MR

术前化疗后结直肠癌肝转移瘤内脂肪的MRI检测

MRI Detection of Intratumoral Fat in Colorectal Liver Metastases After Preoperative Chemotherapy.
PubMed 文献 · AJR Am J Roentgenol · 2018-04-09

回顾性研究纳入59例化疗后行肝切除的结直肠癌肝转移患者,用双回波梯度回波MRI评估瘤内脂肪沉积。化疗前0%(0/20)患者有瘤内脂肪沉积,化疗后54%(32/59)出现。脂肪信号分数≥12%、转移灶≥5个、年龄≥65岁及RECIST 1.1评效为进展或稳定是总生存差的独立预测因素。

要点

  • 化疗后结直肠癌肝转移瘤内脂肪沉积常见,发生率54%(32/59)。
  • 脂肪信号分数≥12%与总生存差独立相关(p=0.01)。
  • 肿瘤最大径≥5cm、钙化及西妥昔单抗或帕尼单抗史预测脂肪信号分数≥12%。

核心结论

  • 术前化疗后的结直肠癌肝转移瘤内脂肪沉积常见,脂肪信号分数≥12%是总生存差的独立预测因素。

研究设计与样本

  • 回顾性影像学研究,经机构审查委员会批准并豁免知情同意,纳入59例化疗后行术前MRI和根治性肝切除的结直肠癌肝转移患者(33男,26女;中位年龄62岁),其中20例另有化疗前MRI。
  • 采用双回波梯度回波MRI评估瘤内脂肪沉积及脂肪沉积最密集区的脂肪信号分数,用多变量分析寻找总生存和化疗后瘤内脂肪沉积的预测因素。

关键影像表现/征象

  • 化疗前0%(0/20)患者有瘤内脂肪沉积,化疗后54%(32/59)患者有瘤内脂肪沉积。

诊断标准与关键数值

  • 总生存差的独立预测因素:转移灶≥5个(p<0.001)、脂肪信号分数≥12%(p=0.01)、年龄≥65岁(p=0.02)、RECIST 1.1评效为进展或稳定(p=0.049)。
  • 化疗后肿瘤脂肪信号分数≥12%的预测因素:最大肿瘤径≥5cm(p=0.005)、肿瘤钙化(p=0.008)、西妥昔单抗或帕尼单抗用药史(p=0.04)。

临床应用与阅片要点

  • 在化疗后结直肠癌肝转移患者的MRI阅片和报告中,应关注双回波梯度回波序列上的瘤内脂肪沉积并测量脂肪信号分数,因其≥12%与总生存差独立相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The objective of this study was to investigate the incidence and clinical significance of intratumoral fat deposition in colorectal liver metastases (CLMs) after preoperative chemotherapy using dual-echo gradient-recalled echo MRI.

MATERIALS AND METHODS: Our institutional review board approved this retrospective radiographic study and waived the requirement for informed patient consent. Fifty-nine patients (33 men, 26 women; median age, 62 years old) who underwent preoperative MRI and curative hepatic resection for colorectal liver metastases after chemotherapy were selected. Twenty patients also underwent MRI before chemotherapy. On dual-echo gradient-recalled echo MR images, intratumoral fat deposition and fat signal fraction at the densest areas of fat deposition in colorectal liver metastases were evaluated. Predictors of overall survival and intratumoral fat deposition after chemotherapy were identified by multivariate analyses.

RESULTS: Before and after chemotherapy, 0 (0%) and 32 (54%) of the patients exhibited intratumoral fat deposition, respectively. Independent predictors of poor overall survival were presence of five or more CLMs (p < 0.001), fat signal fraction of 12% or more (p = 0.01), age of 65 years or older (p = 0.02), and tumor response classified as progressive or stable disease by the Response Evaluation Criteria in Solid Tumors 1.1 (p = 0.049). Predictors of tumor fat signal fraction being 12% or greater after chemotherapy were largest tumor size of 5 cm or more (p = 0.005), tumor calcification (p = 0.008), and history of cetuximab or panitumumab administration (p = 0.04).

CONCLUSION: CLMs after preoperative chemotherapy frequently exhibit intratumoral fat deposition.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Nakai Y, Gonoi W, Hagiwara A, et al. MRI Detection of Intratumoral Fat in Colorectal Liver Metastases After Preoperative Chemotherapy. AJR Am J Roentgenol. 2018. PMID: 29629795. doi:10.2214/AJR.17.18814

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。